News Release：2024 | Eisai Co., Ltd.
WebMar 28, 2024 · Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA. March 29, 2024. EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL. March 28, …
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
WebJan 7, 2023 · LEQEMBI will be available during or before the week of January 23, 2023. Eisai announced the U.S. pricing and rationale for LEQEMBI today. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making …
News Release：2021 | Eisai Co., Ltd.
WebDec 16, 2021 · New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease. November 12, 2021. EISAI PRESENTS NEW ANALYSIS OF LECANEMAB CLINICAL EFFICACY RESULTS FROM PHASE 2B STUDY AT CLINICAL TRIALS ON …
ANTIEPILEPTIC DRUG FYCOMPA® APPROVED IN CHINA FOR ... - eisai…
Web1 day ago · For Print; May 13, 2024; Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa ® (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures …
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET ... - Eisai …
WebSep 28, 2022 · eisai's news release lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early alzheimer’s disease is posted.
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 …
WebNov 30, 2022 · Eisai will discuss the results of Clarity AD study with regulatory authorities in the U.S., Japan and Europe with the aim to file for traditional approval in the U.S. and for marketing authorization applications in Japan and Europe by the end of Eisai’s FY2022, which ends March 31, 2023.
Media center - recent news, blogs, and articles | Eisai US
WebMarch 31, 2024. Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA. Read more > Blog. March 27, 2024. Celebrating the Women Who Are Leading Eisai Today and Into the Future. Read more > explore all …
News Release：2022 | Eisai Co., Ltd.
WebDec 1, 2022 · EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES. December 1, 2022. EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH …
Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for ...
WebJan 7 (Reuters) - The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) for patients in the earliest...
Eisai Newsroom - Press Releases
WebOct 15, 2023 · Eisai Newsroom - Press Releases. Home. > Media Center. > Press Releases. EISAI TO PRESENT NEW DATA FROM LEQEMBI® (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER'S DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) …
Skip to content